跳转至内容
Merck
CN
  • Cystathione β-synthase regulates HIF-1α stability through persulfidation of PHD2.

Cystathione β-synthase regulates HIF-1α stability through persulfidation of PHD2.

Science advances (2020-09-17)
Anindya Dey, Shubhangi Prabhudesai, Yushan Zhang, Geeta Rao, Karthikeyan Thirugnanam, Md Nazir Hossen, Shailendra Kumar Dhar Dwivedi, Ramani Ramchandran, Priyabrata Mukherjee, Resham Bhattacharya
摘要

The stringent expression of the hypoxia inducible factor-1α (HIF-1α) is critical to a variety of pathophysiological conditions. We reveal that, in normoxia, enzymatic action of cystathionine β-synthase (CBS) produces H2S, which persulfidates prolyl hydroxylase 2 (PHD2) at residues Cys21 and Cys33 (zinc finger motif), augmenting prolyl hydroxylase activity. Depleting endogenous H2S either by hypoxia or by inhibiting CBS via chemical or genetic means reduces persulfidation of PHD2 and inhibits activity, preventing hydroxylation of HIF-1α, resulting in stabilization. Our in vitro findings are further supported by the depletion of CBS in the zebrafish model that exhibits axis defects and abnormal intersegmental vessels. Exogenous H2S supplementation rescues both in vitro and in vivo phenotypes. We have identified the persulfidated residues and defined their functional significance in regulating the activity of PHD2 via point mutations. Thus, the CBS/H2S/PHD2 axis may provide therapeutic opportunities for pathologies associated with HIF-1α dysregulation in chronic diseases.

材料
货号
品牌
产品描述

Sigma-Aldrich
抗小鼠IgG(全分子)-过氧化物酶 山羊抗, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
抗-GAPDH 兔抗, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
抗-兔IgG(全分子)-过氧化物酶 山羊抗, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Z-Leu-Leu-Leu-al, ≥90% (HPLC)
Sigma-Aldrich
DMOG, ≥98% (HPLC)
Sigma-Aldrich
Anti-MPST Antibody, clone 1H10.1, clone 1H10.1, from mouse
Sigma-Aldrich
MISSION® esiRNA, targeting human VHL
Sigma-Aldrich
MISSION® esiRNA, targeting human CBS
Sigma-Aldrich
MISSION® esiRNA, targeting human EGLN1